Pfizer sued in US over contraceptive that women say caused brain tumours | Pfizer

Pfizer, a drug producer Pfizer, is facing a US case that develops brain tumors and is brought to women on behalf of women who say that the company is linked to the use of contraceptive injection warehouses.

The class case case claims that if the US pharmaceutical company has been used for more than a year for more than a year, the US pharmaceutical company has been used for more than a year, it does not increase the risk of developing an intracranial meningiomy.

A court hearing will be held in Pensacola, Florida on Monday.

Since May, the number of lawsuits filed by the US against Pfizer against Pfizer, according to the law firm Levin Papantonio, the action has increased more than 1,300 times consolidated in multi -regional cases.

The potential demand value may be several billion dollars, and the number of lawsuits is expected to rise from 5,000 to 10,000 women in the US.

A British Medical Journal In March 2024, the long -term use of some progestogenic drugs was found to be more dependent on the risk of intracranial meningioma, which are tumors formed in tissues around the brain. Medroxiprogesterone acetate sold as warehouse-provera was linked to a risk of 5.6 times higher.

Meningioma is the most common benign brain tumor. They grow slowly and are often not cancerous, but can cause vision or hearing loss, headache and seizures, and often require surgical removal. The surgery carries risks such as potential damage to brain structures near the tumors.

Other studies found a risk associated with Pfizer drug.

The hearing on Monday will deal with the verbal arguments of Levin Papantonio on behalf of affected women and Pfizer on the issue of pre -order. To avoid responsibility, five pilot cases will focus on whether the company can rely on a common prevention defense in drug cases.

Pfizer argues that he is trying to get a tumor warning connected to the label of the drug, but this was rejected by the US regulator, Food and Pharmaceutical Administration (FDA).

The company said in the court applications: “This is a clear preliminary case, because FDA clearly banned from adding a warning about the risk of menengiom, and the plaintiffs state law is necessary.”

The plaintiffs claim that Pfizer’s pre-emme defense failed, because his request to the FDA is very wide, the warehouse-Perrovera group with other low dose hormonal contraceptives, which led to the decision of the regulator not to confirm a tumor warning on the label of the drug in the US label.

It is thought that 247 million women worldwide receive hormonal contraceptives. In the United States, about a quarter of sexually active women have used warehouse-profilera throughout their lives.

Warehouse-Provera, marketed in England since the 1980s Used by 15% of women In the country, also for endometriosis. Warning Tag Updated last year.

Pfizer said he is aware of this potential risk associated with long -term use of progestogens ”and updated label warnings in Canada and Europe.

Virginia Buchanan, the co -chairman of the executive committee of Levin Papantonio and the plaintiff’s executive committee, said: “Pfizer is trying to avoid accountability by starting a preliminary defense, but there are serious questions about whether FDA provides full picture.

“Prevention has never served as a shield for pharmaceutical companies that cannot adequately stimulate patients. Pfizer has not been able to take reasonable steps to warn patients and doctors against this real danger.”

US law firm Berger Montague investigation Whether Pfizer’s board violates trust-based duties in warehouse-provera marketing and sales for a potential shareholder legal transaction.